Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: A focus on rheumatoid arthritis

Expert Opinion on Drug Safety

Volumn 15, Issue , 2016, Pages 55-61

  Tocci, Giuliano ^a,b   Goletti, Delia ^c   Marino, Valentina ^d   Matucci, Andrea ^e   Mariamilano, Giuseppe ^f   Cantini, Fabrizio ^g   Scarpa, Raffaele ^h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d PFIZER INC   (United States)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g MISERICORDIA E DOLCE HOSPITAL   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anti TNF agents; Cardiovascular outcomes; Chronic inflammation; Rheumatic disease; TNF alpha

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; DRUG EFFECT; HEART FAILURE; HUMAN; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; REVIEW; RHEUMATIC DISEASE; SYSTEMATIC REVIEW (TOPIC); ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; VASCULITIS; VENOUS THROMBOEMBOLISM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; VENOUS THROMBOEMBOLISM;

EID: 85011043573     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1218469     Document Type: Review

References (76)

1. Alhusain A, Bruce IN. Cardiovascular risk and inflammatory rheumatic diseases. Clin Med. 2013;13:395–397.
2. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother. 2008;9:1121–1128.
3. Hurlimann D, Enseleit F, Ruschitzka F. [Rheumatoid arthritis, inflammation, and atherosclerosis]. Herz. 2004;29:760–768. [German].
4. Atzeni F, Turiel M, Caporali R, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev. 2010;9:835–839.
5. Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002;46:1714–1719.
6. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46:862–873.
7. Szekanecz Z, Kerekes G, Soltesz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009;5:677–684.
8. Boyer JF, Cantagrel A, Constantin A. Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis. Curr Vasc Pharmacol. 2008;6:218–227.
9. Peters MJ, van Sijl AM, Voskuyl AE, et al. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2012;18:1502–1511. A review summarizing the evidence base, supporting the notion that TNF inhibitors confer benefit CV disease risk in RA.
10. Cugno M, Ingegnoli F, Gualtierotti R, et al. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol. 2010;8:285–292.
11. Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des. 2012;18:1465–1477.
12. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325–331.
13. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
14. Nadkarni A, You M, Resuehr H, et al. The risk for cardiovascular events associated with hyperlipdemia among patients with and without rheumatoid arthritis. J Arthritis. 2015;4:pii: 178.
15. Popa C, Netea MG, Van Riel PL, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48:751–762.
16. Gonzalez-Gay MA, Gonzalez-Juanatey C, Miranda-Filloy JA, et al. Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother. 2006;60:673–677.
17. McKellar GE, McCarey DW, Sattar N, et al. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6:410–417.
18. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005; 64:303–305.
19. Chighizola C, Schioppo T, Ingegnoli F, et al. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis. Curr Vasc Pharmacol. 2012;10:639–646.
20. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156:336–341.
21. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 2002; 20:S152- S157.
22. 2- production. Thromb Haemost. 2003 Aug;90(2):317–325.
23. Mousa SA, Goncharuk O, Miller D. Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Expert Opin Biol Ther. 2007;7:617–625.
24. Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63:1538–1543.
25. Ryan BM, Romberg M, Wolters F, et al. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. Eur J Gastroenterol Hepatol. 2004;16:941–942.
26. Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis. 2005;64:246–252. This article describes about postmarketing safety analysis of etanercept.
27. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889–894. This study describes about large postmarketing safety analysis of adalimumab.
28. Danila MI, Patkar NM, Curtis JR, et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol. 2008;20:327–333.
29. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007;66:880–885.
30. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213–1218.
31. Solomon DH, Curtis JR, Saag KG, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs. Am J Med. 2013;126:730 e9–e17.
32. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576–582. Large registry analysis suggesting that TNF antagonist use was associated with a reduced risk of cardiovascular events in patients with RA.
33. Nurmohamed M, Bao Y, Signorovitch J, et al. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015;1:e000080.
34. Al-Aly Z, Pan H, Zeringue A, et al. Tumor necrosis factor-alpha blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res. 2011;157:10–18. Large analysis of CV outcomes in U.S. veterans treated with anti-TNF agents.
35. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British society for rheumatology biologics register. Arthritis Rheum. 2007;56:2905–2912.
36. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10:R30.
37. Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford). 2014;53:186–194.
38. van Vollenhoven RF. Rheumatologists, take heart! We may be doing something right. Arthritis Res Ther. 2008;10:105.
39. Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67:1449–1455.
40. Myasoedova E, Chandran A, Ilhan B, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis. 2016;75:560–565.
41. Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1813–1818.
42. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:522–529.
43. Armstrong AW, Brezinski EA, Follansbee MR, et al. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20:500–512. A systematic review of the effects of biologic agents on CV outcomes in psoriasis and psoriatic arthritis patients.
44. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005;4:153–161.
45. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011;50:518–531. A systematic review of the effects of TNF antagonists on risk of CV disease in patients with rheumatoid arthritis.
46. Solomon DH, Rassen JA, Kuriya B, et al. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013;72:1813–1818.
47. Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int. 2007;27:369–373.
48. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305–311.
49. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 2008;58:667–677.
50. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–3140.
51. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109:1594–1602.
52. Song SN, Iwahashi M, Tomosugi N, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013;15:R141.
53. Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc. 2012;87:739–745.
54. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol. 2005;61:329–336.
55. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford). 2002;41:116–117.
56. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955–1958.
57. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000;27:2041–2044.
58. Pamies A, Castro S, Poveda MJ, et al. Leucocytoclastic vasculitis associated with golimumab. Rheumatology (Oxford). 2013;52:1921–1923.
59. Mariani N, So A, Aubry-Rozier B. Two cases of Takayasu’s arteritis occurring under anti-TNF therapy. Joint Bone Spine. 2013;80:211–213.
60. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–251.
61. Petitpain N, Gambier N, Wahl D, et al. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng. 2009;19:355–364.
62. Davies R, Galloway JB, Watson KD, et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register. Ann Rheum Dis. 2011;70:1831–1834.
63. Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005; 64:765–766.
64. Seriolo B, Paolino S, Ferrone C, et al. Impact of long-term anti-TNFalpha treatment on insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:159-60; author reply 60.
65. Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1495–1498.
66. Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14:R141.
67. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106:2184–2187.
68. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, et al. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol. 2006;24:309–312.
69. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm. 2012;2012:674265.
70. Sandoo A, van Zanten JJ, Toms TE, et al. Anti-TNFalpha therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord. 2012;13:127.
71. Ahlehoff O, Skov L, Gislason G, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One. 2012;7: e36342.
72. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67:76–85.
73. Primdahl J, Clausen J, Horslev-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis. 2013;72:1771–1776.
74. Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol. 2012;8:13–21.
75. Bernelot Moens SJ, van der Valk FM, Strang AC, et al. Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. Arthritis Res Ther. 2016;18:115.
76. Padfield GJ, Din JN, Koushiappi E, et al. Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: a first in human study. Heart. 2013;99:1330–1335.